Sartorius (FRA:SRT3) has earned a consensus rating of “Hold” from the eleven research firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is €89.27 ($108.87).

A number of equities research analysts have weighed in on the company. Kepler Capital Markets set a €78.00 ($95.12) price objective on Sartorius and gave the company a “neutral” rating in a report on Thursday, January 4th. Commerzbank set a €76.00 ($92.68) price objective on Sartorius and gave the company a “neutral” rating in a report on Wednesday, January 10th. UBS set a €97.00 ($118.29) price objective on Sartorius and gave the company a “neutral” rating in a report on Wednesday, February 14th. Berenberg Bank set a €85.00 ($103.66) price objective on Sartorius and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Hauck & Aufhaeuser set a €60.00 ($73.17) price objective on Sartorius and gave the company a “sell” rating in a report on Wednesday, January 10th.

SRT3 traded down €1.00 ($1.22) during trading on Wednesday, reaching €125.00 ($152.44). The company’s stock had a trading volume of 153,475 shares. Sartorius has a 52-week low of €71.00 ($86.59) and a 52-week high of €124.70 ($152.07).

About Sartorius

Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.